Skip to main content

Nemaura Medical Stock Forecast, Price & News

Notice: Trading of Nemaura Medical halted at 09:42 AM EST due to "LULD pause".
+1.01 (+11.16 %)
(As of 05/12/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume4.30 million shs
Average Volume1.34 million shs
Market Capitalization$230.68 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NMRD News and Ratings via Email

Sign-up to receive the latest news and ratings for Nemaura Medical and its competitors with MarketBeat's FREE daily newsletter.

Nemaura Medical logo

About Nemaura Medical

Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. The company provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as for screening pre-diabetic patients. It has a license agreement with Healthimation, LLC, which licenses the company to make, have made, use, offer to sell, sell, and import intensive medical diabetes and weight management program for Type 2 diabetes, prediabetes, and general wellness; the Why WAIT app; and common law trademarks which incorporate the mark WHY WAIT or WHYWAIT and the use of licensed marks. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.


See More Headlines

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:NMRD
Phone646 416 8000
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Book Value($0.06) per share


Net Income$-4,160,000.00




Market Cap$230.68 million
Next Earnings Date6/29/2021 (Estimated)


Overall MarketRank

0.17 out of 5 stars

Medical Sector

1825th out of 2,045 stocks

Surgical & Medical Instruments Industry

151st out of 169 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Nemaura Medical (NASDAQ:NMRD) Frequently Asked Questions

What stocks does MarketBeat like better than Nemaura Medical?

Wall Street analysts have given Nemaura Medical a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nemaura Medical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Nemaura Medical?

Nemaura Medical saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 444,400 shares, an increase of 33.1% from the March 15th total of 333,800 shares. Based on an average trading volume of 236,100 shares, the days-to-cover ratio is presently 1.9 days. Approximately 5.1% of the shares of the company are sold short.
View Nemaura Medical's Short Interest

When is Nemaura Medical's next earnings date?

Nemaura Medical is scheduled to release its next quarterly earnings announcement on Tuesday, June 29th 2021.
View our earnings forecast for Nemaura Medical

How were Nemaura Medical's earnings last quarter?

Nemaura Medical Inc. (NASDAQ:NMRD) issued its quarterly earnings results on Tuesday, February, 16th. The company reported ($0.06) EPS for the quarter.
View Nemaura Medical's earnings history

How has Nemaura Medical's stock price been impacted by Coronavirus (COVID-19)?

Nemaura Medical's stock was trading at $6.28 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NMRD shares have increased by 60.2% and is now trading at $10.06.
View which stocks have been most impacted by COVID-19

Who are Nemaura Medical's key executives?

Nemaura Medical's management team includes the following people:
  • Dr. Dewan Fazlul Hoque Chowdhury Ph.D., Chairman, CEO & Pres (Age 48, Pay $103.77k)
  • Mr. Justin Mclarney, Chief Fin. Officer
  • Mr. Christopher J. Avery, VP of Global Bus. Operations (Age 58)
  • Mr. Bashir Timol, Chief Bus. Officer & Director (Age 47)
  • Mr. Jay L. Warner, Head of U.S. Commercial Operations
  • Mr. Thomas Bendix Mortensen, Head of E.U. Commercial Operations & Marketing

Who are some of Nemaura Medical's key competitors?

What is Nemaura Medical's stock symbol?

Nemaura Medical trades on the NASDAQ under the ticker symbol "NMRD."

Who are Nemaura Medical's major shareholders?

Nemaura Medical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.65%), Geode Capital Management LLC (0.59%) and Northern Trust Corp (0.37%).

Which institutional investors are buying Nemaura Medical stock?

NMRD stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, BlackRock Inc., and Northern Trust Corp.

How do I buy shares of Nemaura Medical?

Shares of NMRD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nemaura Medical's stock price today?

One share of NMRD stock can currently be purchased for approximately $10.06.

How much money does Nemaura Medical make?

Nemaura Medical has a market capitalization of $230.68 million.

How many employees does Nemaura Medical have?

Nemaura Medical employs 17 workers across the globe.

What is Nemaura Medical's official website?

The official website for Nemaura Medical is

Where are Nemaura Medical's headquarters?

Nemaura Medical is headquartered at 57 WEST 57TH STREET, MANHATTAN NY, 10019.

How can I contact Nemaura Medical?

Nemaura Medical's mailing address is 57 WEST 57TH STREET, MANHATTAN NY, 10019. The company can be reached via phone at 646 416 8000.

This page was last updated on 5/12/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.